Anakinra (NCT04926467)

Name: Anakinra trial for Pancreatic Adenocarcinoma (NCT04926467)
Uploaded: 2026-10-31T16:50:39.815Z
Duration: 1 min 28 s
Description: Anakinra trial for Pancreatic Adenocarcinoma (NCT04926467). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT04926467.

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC): a one-minute explainerNCT049264671 min

Anakinra trial for Pancreatic Adenocarcinoma (NCT04926467). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage I–III pancreatic ductal adenocarcinoma, planned chemotherapy and surgery, and no previous pancreatic-cancer chemotherapy or radiation.

The idea: anakinra blocks interleukin-1 inflammatory signaling. Researchers test it alongside chemotherapy before and after surgery. Before surgery, chemotherapy uses nab-paclitaxel, gemcitabine and cisplatin; afterward, it uses fluorouracil, oxaliplatin and irinotecan. Patients inject anakinra subcutaneously twice daily, holding it two days before surgery. The main measure is normalization of the CA19-9 blood marker after preoperative treatment.

This phase 2 study plans 24 patients. Scott Paulson leads at Baylor’s recruiting Dallas site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.